Interaction of Cimetidine with Cytochrome P450 and Effect on Mixed-Function Oxidase Activities of Liver Microsomes

The histamine H2-receptor antagonist drug, cimetidine (CM), was investigated to determine its effect on the metabolism of 'model' alkoxyphenoxazone substrates ethoxyresorufin (ER) and pentoxyresorufin (PR). The investigation was carried out under different conditions in rat liver microsome...

Full description

Saved in:
Bibliographic Details
Published inHuman & experimental toxicology Vol. 12; no. 2; pp. 147 - 152
Main Authors Faux, S.P., Combes, R.D.
Format Journal Article
LanguageEnglish
Published Thousand Oaks, CA SAGE Publications 01.03.1993
Arnold
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The histamine H2-receptor antagonist drug, cimetidine (CM), was investigated to determine its effect on the metabolism of 'model' alkoxyphenoxazone substrates ethoxyresorufin (ER) and pentoxyresorufin (PR). The investigation was carried out under different conditions in rat liver microsomes from rodents pretreated with various classical cytochrome P450 inducers. CM exerted a dual effect on uninduced and PB-induced liver microsomal ethoxyresorufin-O-de-ethylase (EROD) activities; it was initially stimulatory but became inhibitory. However, when 3-MC-induced preparations were used, CM only exerted an inhibitory effect on EROD activity over the whole concentration range (0.01 μM-20 mM). Pre-incubating PB-induced and uninduced liver microsomes with NADPH before the addition of ER and CM decreased the stimulatory effect of CM and increased the inhibitory effect in the concentration range (5-20 mM). With 3-MC-induced preparations, the inhibition of EROD was only marginally potentiated. Overall conclusions for the diphasic effects of CM on biological activities were due to CM binding with differing affinities to different P450s. Subsequent decreases and increases in stimulation and inhibition, respectively, on pre-incubation with NADPH were thought to be due to an increased affinity of CM for reduced cytochrome P450.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0960-3271
1477-0903
DOI:10.1177/096032719301200209